

# Top 3 Enroller Studywide: Achieving 267% of the Goal in Phase 2 Obesity & T2DM Trial

## Our Objectives

DelRicht Research was selected as a participating site for a Phase 2 Obesity and Type 2 Diabetes trial, focused on enrolling adults aged 18 and older with a confirmed T2DM diagnosis.

- **Total Enrollment Goal:** 216 participants across 48 sites
- **DelRicht Enrollment Goal:** 4.5 participants at 1 site
- **Patient Population:** Participants ages 18+ with T2DM
- **Enrollment Period:** April 2025 – November 2025

## Study Start-Up Timelines




## The Study

**Client:** Midsized Biopharma

**Trial:** US-Based Phase 2 Obesity & T2DM Trial

## Participating PIs



**Dr. Patrick Dennis**  
*Emergency Medicine*  
New Orleans, LA



**New Orleans, LA**  
Touro Medical Center

## Trial Challenges & Solutions

Like many complex clinical trials, this study included operational and patient-selection challenges that required focused strategies to support timely enrollment and adherence to protocol.

### Key Challenge:

Variability in A1c values between prior visits and screening, and ensuring common comorbidities (such as hypertension and hyperlipidemia) are well-controlled.

### How DelRicht Addressed:

Implemented point-of-care A1c testing with prescreening labs and leveraged our database to identify patients stabilized on antihypertensives and statins.

## Our Results

DelRicht completed rapid start-up from **award to activation in 59 days** with seamless sponsor/CRO coordination. The first patient was **screened 5 days post-activation**, and our site **enrolled 12 participants, 267% of target, receiving top 3 enroller recognition**. This demonstrates how **proactive site management drives faster enrollment and stronger sponsor outcomes**.



**12** Participants Enrolled



**#3** Top Enroller Studywide